On September 30, 2021 Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, reported that it will be making an oral poster presentation on the company’s anti IL-38 antibody program at the upcoming joint meeting of the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), being held October 7-10, 2021 (Press release, Immunome, SEP 30, 2021, View Source [SID1234590596]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: "IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody, rescues myeloid cell activation in vitro and induces robust anti-tumor responses in vivo."

Authors: John P. Dowling, et al.

Abstract Number: LBA022

Date/Time: All poster presentations are made available by the conference at the opening of the meeting on October 7, 2021, at 9:00am E.T.

On September 30, 2021 Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported that five abstracts have been selected for presentation as virtual posters at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) on October 7 – 10, 2021 (Press release, Tango Therapeutics, SEP 30, 2021, View Source [SID1234590595]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The preclinical data being presented today highlight the potential applicability of synthetic lethal drug targeting across a range of cancer types. As an example, our lead program, TNG908, an MTA-cooperative PRMT5 inhibitor selective for cancers with deletion of the MTAP gene, shows strong regressions across multiple types of cancer," said Barbara Weber, M.D., president and Chief Executive Officer of Tango Therapeutics. "We look forward to leveraging these data to inform our planned clinical development program."

Dr. Weber will also be co-chairing an Educational session titled "Exploiting Synthetic Lethality" on October 7, 2021 at 10:00 AM ET.

Details on Tango’s presentations at AACR (Free AACR Whitepaper)-NCI-EORTC are as follows:

Poster Title: MTAPnull-selective PRMT5 inhibitors drive regressions in MTAP-deleted xenograft models across histologies
Abstract #: P214
Date and Time: October 7, 9:00 AM ET

Poster Title: VRK1 is a novel synthetic lethal target in VRK2-methylated glioblastoma
Abstract #: P182
Date and Time: October 7, 9:00 AM ET

Poster Title: CRISPR screens identify sensitizers to Trametinib in KRAS mutant cancer cell lines
Abstract #: P183
Date and Time: October 7, 9:00 AM ET

Poster Title: Loss of HS2ST1 cooperates with MAPK inhibition to impair growth of mesenchymal KRAS mutant NSCLC
Abstract #: P146
Date and Time: October 7, 9:00 AM ET

Poster Title: Isogenic CRISPR Anchor Screens identified actionable nodes to CHK1/2 inhibitor Prexasertib in TP53 mutant cancer
Abstract #: P095
Date and Time: October 7, 9:00 AM ET

On September 30, 2021 CatalYm reported that a data update from their ongoing first-in-human trial "GDFather" (GDF-15 Antibody-mediated Effector cell Relocation) has been accepted for oral presentation at the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) (Press release, Catalym, SEP 30, 2021, View Source [SID1234590594]). The conference will be held virtually from October 7 -10, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"GDF-15 is frequently overexpressed in various tumor types and appears to play a central role in suppressing several key mechanisms by which the immune system recognizes and eliminates tumors, making it an exciting target in immuno-oncology drug development. We look forward to presenting an update from this trial to the scientific community in an oral plenary session," said Eugen Leo, MD, PhD, MBA, Chief Medical Officer at CatalYm.

Details of the oral presentation:

Presentation title: A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors

Session title: New Drugs on the Horizon II

Speaker: Eugen Leo, MD, PhD, MBA, Chief Medical Officer of CatalYm

Date/time: October 9, 2021, at 4.05 pm ET/22.05 pm CEST

About the GDFather Trial

The ongoing first-in-human GDFather trial (GDF-15 Antibody-mediaTed Effector cell Relocation) is a two-part, open-label study to evaluate GDF-15 inhibitor CTL002 in advanced, checkpoint inhibitor refractory or relapsed solid tumor patients. In the dose escalation phase (Part A), up to 24 patients will receive escalating doses of CTL-002 in a "3+3" manner with the lead candidate given as a monotherapy and followed by combination with an anti-PD-1 checkpoint inhibitor. In the second dose expansion phase (Part B, phase 2a), several cohorts with tumors identified to be GDF-15-dependent will be treated to further evaluate safety and preliminary efficacy of CTL-002 treatment.

About CTL-002

CTL-002 is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 secretion by the tumor has been shown to prevent T cell migration into the tumor and suppresses T cell function and the adaptive immune response in the tumor microenvironment. All these mechanisms help the tumor evade the immune system and become resistant to standard of care and current immunotherapy approaches such as checkpoint inhibitors. CTL-002 counteracts these immuno-suppressive mechanisms by neutralizing GDF-15, enhancing the infiltration of immune cells into the tumor, improving both priming of T cells by dendritic cells and tumor killing by T cells and NK cells.

On September 30, 2021 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, reported that it has been selected for an oral presentation of initial monotherapy clinical data from its ongoing Phase 1/2 clinical trial of RP-3500 and a poster presentation of preclinical data for RP-3500 at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), being held October 7-10, 2021 (Press release, Repare Therapeutics, SEP 30, 2021, View Source [SID1234590593]). In addition, the Company will be hosting a Virtual Investor Webcast Event on Friday, October 8, 2021 at 5:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Details on RP-3500 Early TRESR Monotherapy Trial Results:
Title: First-in-Human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations
Presenter: Dr. Timothy Yap, MBBS, Ph.D., FRCP, Medical Director, Institute for Applied Cancer Science, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas
Abstract Number: 4950
Session Title: Concurrent Session 04: Novel Precision Medicine Combination Trials
Date/Time: Friday, October 8, 2021 at 3:15 p.m. ET

Poster Presentation Details on Preclinical data for RP-3500 Alone and in Combination with PARP Inhibitors:
Title: RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Pre-Clinical Models as a Monotherapy and in Combination with PARP Inhibitors
Presenter: Anne Roulston, Ph.D., Repare Therapeutics
Poster Number: P054
Date/Time: Thursday, October 7, 2021, at 9:00 a.m. ET

Company Virtual Investor Webcast Event Details:

The Company will host a virtual investor webcast on Friday, October 8, 2021 at 5:00 p.m. ET to further discuss the initial monotherapy RP-3500 data that will be presented at the AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper). Repare’s executive management team will be joined by Dr. Timothy Yap, MBBS, Ph.D., FRCP, MD Anderson Cancer Center, Houston, Texas.

A live video webcast and presentation slides will be available on the Investor section of the Company’s website at View Source A webcast replay will also be available for at least 30 days following the call.

About RP-3500

RP-3500 is a potent and selective oral small molecule inhibitor of ATR (Ataxia Telangiectasia and Rad3 related protein kinase) being developed for the treatment of solid tumors with specific genome instability related genomic alterations including those in the ATM (ataxia-telangiectasia mutated) gene.

About Repare Therapeutics’ SNIPRx Platform

Repare’s SNIPRx platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.

On September 30, 2021 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that interim Phase I results from its Phase I/II trial of BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, has been selected for a plenary oral presentation at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), being held October 7-10, 2021 (Press release, Bicycle Therapeutics, SEP 30, 2021, View Source [SID1234590592]). The Company will host a conference call to discuss the results and provide an update on preliminary findings from the BT8009 program on Thursday, October 7, 2021 at 3:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AACR-NCI-EORTC Plenary Oral Presentation Details:
Title: A first in class phase I/II Study of the Novel Bicyclic Peptide and MMAE Conjugate, BT5528, in patients with Advanced Malignancies Associated with EphA2 Expression
Presenter: Meredith McKean, M.D., Sarah Cannon Research Institute at Tennessee Oncology
Session Title: Tumor-targeted Conjugates: A Growing Family
Date/Time: Thursday, October 7 at 12:50 p.m. ET

Conference Call Details
Bicycle Therapeutics will host a conference call and webcast on Thursday, October 7 at 3:00 p.m. ET to review the data being presented and provide an update on preliminary findings from the BT8009 program. To access the call, please dial (800) 377-9118 (domestic) or (409) 937-8920 (international) and provide the Conference ID 2287246. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com.